Abstract
Lung cancer is the leading cause of cancer death for both men and women in the United States, and similar trends are seen world wide. The lack of early diagnosis is one of the primary reasons for the high mortality rate. A number of biomarkers have been evaluated in lung cancer patients, however, their specificity and early stage diagnostic values are limited. Using traditional protein chemistry and proteomics tool we have demonstrated higher serum haptoglobin levels in small cell lung cancer (SCLC). Similar findings have been reported for other cancers including ovarian cancer and glioblastoma. Haptoglobin is an acute phase protein with at least six possible phenotypes. The six phenotypes, in combination with two post translational modifications, glycosylation and deamidation, lead to large numbers of possible haptoglobin isoforms. Recent studies indicate a possible correlation between specific haptoglobin glycosylation and particular disease conditions. In our current study, we have fractionated control and SCLC patient serum by 2-D gel electrophoresis to identify differentially expressed haptoglobin isoforms in SCLC serum samples.
Keywords: Serum, haptoglobin, Isoforms, small cell lung cancer
Current Proteomics
Title: Differential Serum Level of Specific Haptoglobin Isoforms in Small Cell Lung Cancer
Volume: 7 Issue: 1
Author(s): Ankur Shah, Harpreet Singh, Vibhu Sachdev, James Lee, Sohiya Yotsukura, Ravi Salgia and Ajit Bharti
Affiliation:
Keywords: Serum, haptoglobin, Isoforms, small cell lung cancer
Abstract: Lung cancer is the leading cause of cancer death for both men and women in the United States, and similar trends are seen world wide. The lack of early diagnosis is one of the primary reasons for the high mortality rate. A number of biomarkers have been evaluated in lung cancer patients, however, their specificity and early stage diagnostic values are limited. Using traditional protein chemistry and proteomics tool we have demonstrated higher serum haptoglobin levels in small cell lung cancer (SCLC). Similar findings have been reported for other cancers including ovarian cancer and glioblastoma. Haptoglobin is an acute phase protein with at least six possible phenotypes. The six phenotypes, in combination with two post translational modifications, glycosylation and deamidation, lead to large numbers of possible haptoglobin isoforms. Recent studies indicate a possible correlation between specific haptoglobin glycosylation and particular disease conditions. In our current study, we have fractionated control and SCLC patient serum by 2-D gel electrophoresis to identify differentially expressed haptoglobin isoforms in SCLC serum samples.
Export Options
About this article
Cite this article as:
Shah Ankur, Singh Harpreet, Sachdev Vibhu, Lee James, Yotsukura Sohiya, Salgia Ravi and Bharti Ajit, Differential Serum Level of Specific Haptoglobin Isoforms in Small Cell Lung Cancer, Current Proteomics 2010; 7 (1) . https://dx.doi.org/10.2174/157016410790979635
DOI https://dx.doi.org/10.2174/157016410790979635 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Combinatorial Protein Biochemistry for Therapeutics and Proteomics
Current Pharmaceutical Biotechnology Pharmacokinetic and Pharmacogenetic Predictive Markers of Irinotecan Activity and Toxicity
Current Drug Metabolism Cytochrome P450-Activated Prodrugs: Targeted Drug Delivery
Current Medicinal Chemistry Viral Vectors in Cancer Immunotherapy: Which Vector for Which Strategy?
Current Gene Therapy Epidemiological Evidence Associating Secondhand Smoke Exposure with Cardiovascular Disease
Inflammation & Allergy - Drug Targets (Discontinued) Polyaromatic Hydrocarbons (PAHs): Structures, Synthesis and their Biological Profile
Current Organic Synthesis Molecule of the Month
Current Topics in Medicinal Chemistry Functions of Antimicrobial Peptides in Vertebrates
Current Protein & Peptide Science Molecular Targets from VHL Studies into the Oxygen-Sensing Pathway
Current Cancer Drug Targets Chemoradiotherapy in Locally Advanced, Unresectable Non-Small Cell Lung Cancer
Reviews on Recent Clinical Trials Comprehensive DNA Methylation-transcriptome Profiles Association Analysis During the Treatment of Acute Myelocytic Leukemia
Current Pharmaceutical Design The Structure and Function of Histone Deacetylases: The Target for Anti-cancer Therapy
Current Medicinal Chemistry Multiple-line Chemotherapy and Tyrosine Kinase Inhibitor Treatment in Patients with Advanced Lung Cancer
Combinatorial Chemistry & High Throughput Screening Discovery of New Biomarkers of Cancer Using Proteomics Technology
Current Cancer Therapy Reviews Diverse Roles of GADD45α in Stress Signaling
Current Protein & Peptide Science The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy
Current Drug Metabolism Proteomics Approach to Illustrate Drug Action Mechanisms
Current Drug Discovery Technologies Pharmacokinetic Analysis of Taxane Through a Validated Ultra-High Performance Liquid Chromatography-Synapt Mass Spectrometry (UHPLC-MS/MS ESI-Q-TOF) Method
Current Bioactive Compounds Modifying Toll-like Receptor 9 Signaling for Therapeutic Use
Mini-Reviews in Medicinal Chemistry Electrochemical Study of Ellipticine Interaction with Single and Double Stranded Oligonucleotides
Anti-Cancer Agents in Medicinal Chemistry